Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.

RHHBY wins approval for prefilled syringe of ophthalmology drug Vabysmo for three retinal conditions that can cause blindness.

Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.

Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can ...

Trastuzumab (Herceptin) was approved for the European market by Roche in August 2000 to treat patients with early-stage and ...

SHR-A1811 showed promising antitumor activity and acceptable tolerability in patients with HER2-positive breast cancer, ...

Ann Marie Rogers won a landmark victory to make the breast cancer drug Herceptin more widely available. Here, she explains what drove her. But others are asking if the treatment really lives up to ...

The drug binds two HER2 epitopes that are also separately targeted by Roche’s blockbuster HER2 antibodies Herceptin and Perjeta. Compared with the combination of Herceptin and Perjeta ...

Halozyme's fabless model, leveraging its ENHANZE technology, has driven significant growth, similar to successful semiconductor companies like NVIDIA and Broadcom. The recent acquisition of Evotec ...

in addition to strong preclinical data demonstrating efficacy on a standalone basis and in combination with HER2-targeting therapeutic antibodies such as Herceptin®. Third Quarter Corporate ...

A new treatment for Duchenne muscular dystrophy (DMD) is set to be available to around 1,700 people in England following positive final draft guidance from NICE published today. Working alongside ...

Medically reviewed by Lindsay Cook, PharmD If you have HER2-positive breast cancer, your options for treatment will depend on ...